Quick Answer
Crinetics Pharmaceuticals, Inc. reported Total Assets of $1.13 billion for the year ending 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -21.5% in Total Assets from 2024 to 2025.
- This data is from Crinetics Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $74.70 million | Q3 2018: $176.68 million | Q1 2019: $166.76 million | Q2 2019: $155.15 million | Q3 2019: $142.51 million | Q1 2020: $123.88 million | Q2 2020: $217.12 million | Q3 2020: $200.32 million | Q1 2021: $163.55 million | Q2 2021: $216.93 million | Q3 2021: $209.36 million | Q1 2022: $333.29 million | Q2 2022: $421.73 million | Q3 2022: $384.88 million | Q1 2023: $314.01 million | Q2 2023: $293.25 million | Q3 2023: $641.54 million | Q1 2024: $978.15 million | Q2 2024: $935.54 million | Q3 2024: $937.37 million | Q1 2025: $1.36 billion | Q2 2025: $1.29 billion | Q3 2025: $1.20 billion.
- Over the full 9 years of available data (2017 to 2025), Crinetics Pharmaceuticals, Inc.'s Total Assets has grown by 7,120.5%.
- Historical annual values: Fiscal year 2025: $1.13 billion | Fiscal year 2024: $1.43 billion | Fiscal year 2023: $635.35 million | Fiscal year 2022: $352.18 million | Fiscal year 2021: $351.02 million | Fiscal year 2020: $183.45 million | Fiscal year 2019: $130.38 million | Fiscal year 2018: $171.42 million | Fiscal year 2017: $15.60 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: